EuroBiotech: More Articles of Note

newspapers
(Pixabay)

> Affimed dosed the first patient in a phase 1/2a clinical trial of its innate cell redirecting immuno-oncology candidate AFM24. The trial is enrolling patients with solid tumors that express EGFR. Release 

> The FDA accepted Autolus Therapeutics’ filing to study AUTO1 in adults with acute lymphoblastic leukemia. Autolus expects COVID-19 to have minimal impact on the study. Statement  

> Synthon Biopharmaceuticals rebranded as Byondis. The Dutch biotech is closing in on data from a phase 3 trial of its anti-HER2 antibody-drug conjugate SYD985. Release 

Virtual Roundtable

ASCO Explained: Expert predictions and takeaways from the world's biggest cancer meeting

Join FiercePharma for our ASCO pre- and post-show webinar series. We'll bring together a panel of experts to preview what to watch for at ASCO. Cancer experts will highlight closely watched data sets to be unveiled at the virtual meeting--and discuss how they could change prescribing patterns. Following the meeting, we’ll do a post-show wrap up to break down the biggest data that came out over the weekend, as well as the implications they could have for prescribers, patients and drugmakers.

> Mayne Pharma filed for FDA approval of E4/DRSP, a combined oral contraceptive that is partnered with Belgium’s Mithra Pharmaceuticals. Statement 

> Kymab claimed a win in its patent dispute with Regeneron. The case centers on patents for genetically modified mice and antibodies taken from them. Release 

> Sosei Heptares began applying its structure-based drug design platform to the discovery of inhibitors of SARS-CoV-2 protease. The biotech will make its findings freely available. Statement 

Suggested Articles

Inovio CEO J. Joseph Kim is undeterred by short sellers and other detractors who doubt his company can shuttle a COVID-19 DNA vaccine to market.

Adding entinostat to hormone therapy did not help patients with HR-positive, HER2-negative breast cancer live longer.

The data add to the evidence in support of the IL-6 drug ahead of a FDA decision to approve it in a rare disease served by Alexion’s Soliris.